染色体微阵列分析产前诊断
染色体微阵列分析(CMA)可通过阵列比较基因组杂交或单核苷酸多态性阵列完成,在产前检测主要染色体失衡方面与传统核型分析相当,并能发现标准G显带核型分析无法识别的亚显微失衡(微缺失/微重复)。在核型正常的产前诊断样本中,CMA在约1%结构正常妊娠和6%结构异常妊娠中诊断出有临床意义的亚染色体缺失或重复;检测前遗传咨询对解读复杂结果及区分CMA与非侵入性产前检测的优劣至关重要。
要点
- CMA在产前检测非整倍体和不平衡重排方面与传统核型分析相当。
- 核型正常时,CMA在约1%结构正常妊娠和6%结构异常妊娠中检出有临床意义的亚染色体缺失或重复。
- 检测前遗传咨询有助于解读复杂结果并区分CMA与cfDNA非侵入性产前检测的差异。
核心结论
- CMA在产前检测主要染色体失衡方面与传统核型分析相当,并能额外发现亚显微失衡;在核型正常的产前诊断样本中,约1%结构正常妊娠和6%结构异常妊娠可检出有临床意义的亚染色体缺失或重复。
研究设计与样本
- 原文未报告研究设计。
主要发现
- CMA可通过阵列比较基因组杂交或单核苷酸多态性阵列完成。
- 在产前检测主要染色体失衡(如非整倍体和不平衡重排)方面,CMA与传统核型分析相当。
- CMA能揭示标准G显带染色体标本无法看到的亚显微失衡或拷贝数变异,即微缺失和微重复。
- 微缺失/微重复的临床意义不一:部分为良性,部分与从良性到严重的临床表型谱相关,部分临床意义未知。
- 在核型正常的产前诊断样本中,CMA在约1%结构正常妊娠和6%结构异常妊娠中诊断出有临床意义的亚染色体缺失或重复。
关键数值与推荐
- 在核型正常的产前诊断样本中,CMA诊断有临床意义的亚染色体缺失或重复的比例:结构正常妊娠约1%,结构异常妊娠6%。
临床怎么用
- 检测前遗传咨询有助于传达复杂的CMA结果。
- 检测前咨询有助于区分CMA与非侵入性产前检测(使用游离胎儿DNA)在益处、局限性和诊断范围上的主要差异。
局限性
- 并非所有微缺失/微重复都与不良临床表型相关,许多情况下为良性。
- 部分微缺失/微重复与从良性到严重的临床表型谱相关,部分临床意义未知。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Chromosomal microarray analysis (CMA) is performed either by array comparative genomic hybridization or by using a single nucleotide polymorphism array. In the prenatal setting, CMA is on par with traditional karyotyping for detection of major chromosomal imbalances such as aneuploidy and unbalanced rearrangements. CMA offers additional diagnostic benefits by revealing sub-microscopic imbalances or copy number variations that are too small to be seen on a standard G-banded chromosome preparation. These submicroscopic imbalances are also referred to as microdeletions and microduplications, particularly when they include specific genomic regions that are associated with clinical sequelae. Not all microdeletions/duplications are associated with adverse clinical phenotypes and in many cases, their presence is benign. In other cases, they are associated with a spectrum of clinical phenotypes that may range from benign to severe, while in some situations, the clinical significance may simply be unknown. These scenarios present a challenge for prenatal diagnosis, and genetic counseling prior to prenatal CMA greatly facilitates delivery of complex results. In prenatal diagnostic samples with a normal karyotype, chromosomal microarray will diagnose a clinically significant subchromosomal deletion or duplication in approximately 1% of structurally normal pregnancies and 6% with a structural anomaly. Pre-test counseling is also necessary to distinguish the primary differences between the benefits, limitations and diagnostic scope of CMA versus the powerful but limited screening nature of non-invasive prenatal diagnosis using cell-free fetal DNA.
引用
- Levy B, Wapner R. Prenatal diagnosis by chromosomal microarray analysis. Fertil Steril. 2018. PMID: 29447663. doi:10.1016/j.fertnstert.2018.01.005
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。